Zhejiang Sunflower Great Health Co., Ltd Class A

Zhejiang Sunflower Great Health Co., Ltd Class A

SSZSE:300111
2.90
CNY
-0.20
(-6.45%)
-0.02EPS
3.84BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.11
1.32
1.67
1.57
1.29
0.8
0.73
0.26
0.27
0.29
0.26
0.25
0.19
0.19
Basic EPS, GAAP
0.04
0.03
0.08
0.03
0.02
-1
-0.1
0.05
0.05
- -
0.02
0.01
- -
-0.02
Free Cash Flow per Basic Share
-0.11
-0.03
0.17
0.31
0.14
0.06
0.03
0.03
0.07
-0.02
-0.01
0.01
- -
- -
Dividend per Share
0.09
0.06
0.07
0.06
0.03
0.03
0.03
0.02
- -
- -
- -
- -
- -
- -
Book Value per Share
1.04
1.05
1.13
1.16
1.17
0.34
0.04
0.13
0.26
0.26
0.53
0.53
0.53
0.52
Tangible Book Value per Share
0.89
0.92
1.01
1.05
1.07
0.26
0.03
0.12
0.24
0.2
0.48
0.49
0.49
0.47
Basic Weighted Avg Shares
1,015
1,249
1,095
1,021
1,185
1,125
1,149
1,117
1,113
1,139
1,279
1,305
1,462
1,283
Sales/Revenue/Turnover
1,123
1,644
1,824
1,603
1,530
900
837
287
297
336
338
330
272
244
Operating Margin (%)
2.61
7.02
12.43
10.42
1.05
-14.54
3.68
7.4
5.2
-0.54
-6.85
-1.55
-2.2
-2.16
Depreciation Expense
123
147
158
160
161
158
67
19
20
16
18
18
15
- -
Net Income, GAAP
41
37
88
31
24
-1,125
-115
56
53
-1
22
8
-4
-21
Effective Tax Rate (%)
1.19
3.53
17.78
41.87
- -
- -
- -
5.06
4.96
1.54
3.98
- -
- -
- -
Profit Margin (%)
3.62
2.28
4.8
1.91
1.55
-124.94
-13.74
19.47
17.97
-0.34
6.43
2.37
-1.61
-8.75
Working Capital
-219
-292
-156
- -
48
267
92
194
344
293
688
652
662
636
LT Debt
444
212
172
147
123
91
- -
1
- -
2
1
- -
- -
- -
Total Equity
1,161
1,176
1,266
1,301
1,313
485
172
271
410
415
810
823
819
806
Return on Invested Capital (%)
1.3
1.41
3.72
2.41
- -
- -
- -
46.87
20.17
1.59
4.09
- -
- -
- -
Return on Capital (%)
5.63
5.49
6.67
2.94
- -
- -
- -
16.77
11.99
-1.49
3.67
- -
- -
- -
Return on Common Equity (%)
3.55
3.21
7.18
2.39
1.81
-132.6
-53.1
55.73
24.44
-0.4
4.51
1.15
-0.64
-3.15

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
- -
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,287
1,287
1,287
Market Capitalization
5,187
3,707
3,836

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
772
790
746
Cash, Cash Equivalents & STI
501
508
484
Accounts Receivable, Net
38
37
47
Inventories
174
193
169
Total Current Liabilities
115
134
111
Payables & Accruals
- -
- -
- -
ST Debt
- -
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.27%
29.76%
-0.46%
Free Cash Flow
-59.25%
-98.84%
-129.97%
Net Income, GAAP
-750.8%
-467.3%
-156.02%
Sales/Revenue/Turnover
-13.35%
-0.57%
-17.81%
Total Cash Common Dividend
63.99%
152.73%
-99.24%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
84
74
69
103
330
2025
72
72
- -
72
272
2026
55
54
63
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.01
2025
- -
- -
- -
- -
- -
2026
- -
-0.01
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Hua Xin Shi
Full Time Employees
303
Sector
Producer manufacturing
Industry
Electrical products
Address
Sanjiang Road Shaoxing ZJ China 312071
IPO Date
Aug 13, 2010
Website
sunowe.com
Business
Zhejiang Sunflower Great Health Co Ltd (300111.SZ), formerly Zhejiang Sunflower Great Health LLC and changed to its current name in December 2023, principally engages in the research, development, production and sales of pharmaceutical products focused on anti-infective, cardiovascular and digestive system drugs; key offerings include clarithromycin active pharmaceutical ingredient and tablets, azithromycin dispersible tablets and for injection, roxithromycin capsules, lacidipine dispersible tablets, simvastatin tablets, omeprazole sodium for injection and famotidine for injection, which treat infectious diseases such as pneumonia and bronchitis, hypertension, hypercholesterolemia and gastrointestinal conditions including ulcers and reflux esophagitis. Founded in 2005 and headquartered at Sanjiang Road, Paojiang Industrial Zone, Shaoxing, Zhejiang Province, China, the company primarily serves domestic and overseas markets in the healthcare sector with approximately 331 employees and operates through subsidiaries including Zhejiang Beide Pharmaceutical Co Ltd, whose pharmaceutical production license was recently updated. In September 2025, the company announces plans to acquire 100% equity of Zhangzhou Xipu Materials Technology Co Ltd, a producer of electronic-grade semiconductor materials, and the remaining 40% equity of Zhejiang Beide Pharmaceutical Co Ltd to make it wholly-owned, alongside raising supporting funds through share issuance and cash payments, marking a strategic expansion into high-tech industries beyond pharmaceuticals.